Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Intrahepatic Cholangiocellular Carcinoma
ChiCTR2000035916Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Sep 2020
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bortezomib in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: survival time. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
bortezomib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2000035916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035916.